AUDIOCURE-PHARMA-GMBH
22.5.2017 13:14:11 CEST | Business Wire | Press release
AudioCure, a German pharmaceutical company focusing on the development of treatments for hearing disorders, announced today that it has appointed Dr. Reimar Schlingensiepen as CEO.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170522005541/en/
Dr. Schlingensiepen has been with AudioCure as COO since July 2015. During that time, he has successfully reshaped the company and carved out the recent series A financing round of about 9 million euros. He takes over from Prof. Hans Rommelspacher, who will continue as CSO. “With Reimar´s deep commitment to AudioCure, his proven track record and over 20 years of experience in the biopharmaceutical industry spanning preclinical, clinical and product development, I could not have wished for a better person for the job of CEO,” said Prof. Rommelspacher.
Since 2008, Dr. Schlingensiepen has worked as entrepreneur and manager in the fields of biopharmaceutical development, med-tech and diagnostics. He co-founded a number of high-tech companies, where he held several management positions. In addition to his leadership and biopharmaceutical expertise, he brings to AudioCure substantial experience in manufacturing, marketing and finance. It is of great advantage to AudioCure that, as a medical doctor, Dr. Schlingensiepen also conducted a variety of clinical trials in oncology, immunology and neurology.
With AudioCure, Dr. Schlingensiepen´s immediate goal is to steer the company’s first in class front-runner molecule AC102 through its formal preclinical development. This is a prerequisite for the clinical development, which is planned in patients with auditory disorders including acute hearing loss and acute tinnitus.
“With the proof of principle for AC102 accomplished under the leadership of Prof. Rommelspacher, this is an exciting time in AudioCure’s development. We hold a gem in our hands with enormous potential for patients suffering from auditory disorders,” said Dr. Schlingensiepen. “In sharing responsibilities, Hans and I can continue on our seamless path to the clinic. I am very much looking forward to leading an AudioCure team that recognizes the unique opportunity we have to help transform the treatment landscape for hearing impairments.”
For further information: www.audiocure.de .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005541/en/
Contact:
AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 39714
E-Mail:
pr@audiocure.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
Klarna Submits Application for U.S. Banking License6.7.2026 14:30:00 CEST | Press release
Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon
IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises6.7.2026 14:00:00 CEST | Press release
This is a strategic asset acquisition comprising proprietary software and intellectual property of Quantistry GmbH, a pioneer in cloud-native, AI-powered chemical and materials simulation By integrating Quantistry’s advanced simulation platform with IQM’s leading quantum computing hardware, IQM will deliver an end-to-end quantum-classical applications development platform and algorithm libraries powered by a user-friendly native-AI computing environment The transaction secures a critical enterprise software layer that accelerates IQM’s application roadmap, enabling industrial enterprises to develop quantum application proof-of-concepts and scale them over time, backed by a reliable, long-term quantum roadmap It also enhances IQM’s ability to deepen domain expertise across specific industry verticals Quantistry’s core quantum chemistry and machine learning engineering team will join IQM, strengthening the company’s ability to deepen relationships with tier-one industrial enterprises acr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom